CO6180441A2 - Inhibidores nucleosidos del hcv - Google Patents
Inhibidores nucleosidos del hcvInfo
- Publication number
- CO6180441A2 CO6180441A2 CO09033094A CO09033094A CO6180441A2 CO 6180441 A2 CO6180441 A2 CO 6180441A2 CO 09033094 A CO09033094 A CO 09033094A CO 09033094 A CO09033094 A CO 09033094A CO 6180441 A2 CO6180441 A2 CO 6180441A2
- Authority
- CO
- Colombia
- Prior art keywords
- hydrogen
- compound according
- cor4
- phenyl
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1.- Un compuesto de fórmula Idonde: R1, R2 y R3 se seleccionan en forma independiente entre el grupo que consiste en hidrógeno, COR4, C(=O)OR4 y C(=O)CHR5NHR6; o R1 y R3 son H y R2 es el éster monofosfato, difosfato o trifosfato; R4 se selecciona en forma independiente entre el grupo que consiste en (a) C1-18 alquilo lineal o ramificado, (b) C1-18 haloalquilo, (c) C3-8 cicloalquilo, (d) C1-10 heteroalquilo y (e) fenilo donde dicho fenilo está opcionalmente sustituido con entre uno y tres grupos seleccionados en forma independiente entre C1-3 alquilo, C1-3 alcoxi, halógeno, ciano o nitro; R5 es hidrógeno, C1-10 alquilo, fenilo o C1-3 fenilalquilo donde dicho fenilo está opcionalmente sustituido con entre uno y tres grupos seleccionados en forma independiente entre el grupo que consiste en halógeno, hidroxi, C1-3 alcoxi, C1-3 alquilo, ciano y nitro; R6 es hidrógeno o C1-6 alcoxi; o, sales de adición ácida del mismo. 2.- Un compuesto de acuerdo con la reivindicación 1 en donde R1, R2 y R3 son en cada caso hidrógeno. 3.- Un compuesto de acuerdo con la reivindicación 1 en donde R1, R2 y R3 son cada uno en forma independiente hidrógeno, OCR4 o C(=O)OR4. 4.- Un compuesto de acuerdo con la reivindicación 3 en donde R4 es C1-10 alquilo lineal o ramificado. 5.- Un compuesto de acuerdo con la reivindicación 1 en donde R1 es hidrógeno y R2 y R3 son COR4. 6.- Un compuesto de acuerdo con la reivindicación 1 en donde R1 es hidrógeno, R2 y R3 son COR4 y R4 es alquilo lineal o ramificado; o una sal farmacéuticamente aceptable del mismo. 7.- Un compuesto de acuerdo con la reivindicación 1 en donde R1 y R3 son hidrógeno R2 se selecciona entre el grupo que consiste en COR4, C(=O)OR4 y COCH(R5)NHR6. 8.- Un compuesto de acuerdo con la reivindicación 7 en donde R2 es COCH(R5)NHR6, R5 es iso-propilo, iso-butilo o sec-butilo y R6 es hidrógeno. 9.- Un compuesto de acuerdo con la reivindicación 8 en donde R5 tiene la estereoquímica de un L-aminoácido. 10.- Un compuesto de acuerdo con la reivindicación 7, en donde R2 es OCR4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85092606P | 2006-10-10 | 2006-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6180441A2 true CO6180441A2 (es) | 2010-07-19 |
Family
ID=38925483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09033094A CO6180441A2 (es) | 2006-10-10 | 2009-03-31 | Inhibidores nucleosidos del hcv |
Country Status (32)
Country | Link |
---|---|
US (4) | US7666856B2 (es) |
EP (2) | EP2361922B1 (es) |
JP (2) | JP2010505902A (es) |
KR (1) | KR20090078347A (es) |
CN (2) | CN101573370B (es) |
AP (1) | AP2009004812A0 (es) |
AT (1) | ATE493428T1 (es) |
AU (1) | AU2007306405A1 (es) |
BR (1) | BRPI0719258A2 (es) |
CA (1) | CA2665049C (es) |
CO (1) | CO6180441A2 (es) |
CR (1) | CR10789A (es) |
CY (1) | CY1111342T1 (es) |
DE (1) | DE602007011658D1 (es) |
DK (1) | DK2084175T3 (es) |
EA (1) | EA018935B1 (es) |
ES (2) | ES2358853T3 (es) |
GT (1) | GT200900069A (es) |
HK (2) | HK1137459A1 (es) |
HN (1) | HN2009000614A (es) |
HR (1) | HRP20110193T1 (es) |
IL (1) | IL197907A0 (es) |
MX (1) | MX2009003452A (es) |
MY (1) | MY145314A (es) |
NO (1) | NO20091834L (es) |
NZ (1) | NZ575889A (es) |
PL (2) | PL2361922T3 (es) |
PT (1) | PT2084175E (es) |
RS (1) | RS51643B (es) |
SI (1) | SI2084175T1 (es) |
WO (1) | WO2008043704A1 (es) |
ZA (1) | ZA200902496B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2009004812A0 (en) * | 2006-10-10 | 2009-04-30 | Medivir Ab | HCV nucleoside inhibitor |
CN100532388C (zh) * | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
AR072428A1 (es) | 2008-07-01 | 2010-08-25 | Medivir Ab | Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos. |
TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作c型肝炎病毒抑制劑之巨環吲哚衍生物 |
EP2166016A1 (en) | 2008-09-18 | 2010-03-24 | Centocor Ortho Biotech Products L.P. | Phosphoramidate Derivatives of Nucleosides |
TW201023858A (en) * | 2008-09-18 | 2010-07-01 | Ortho Mcneil Janssen Pharm | Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside |
PA8852101A1 (es) | 2008-12-08 | 2010-07-27 | Medivir Ab | Nucleótidos uracil ciclopropílicos |
DE102009028015A1 (de) * | 2009-07-24 | 2011-01-27 | Virologik Gmbh | Mittel zur Behandlung von Hepatitis C-Infektionen |
US8552021B2 (en) | 2009-09-29 | 2013-10-08 | Janssen Products, L.P. | Phosphoramidate derivatives of nucleosides |
KR20130057990A (ko) | 2010-04-13 | 2013-06-03 | 얀센 파마슈티칼즈, 인코포레이티드 | 마크로사이클릭 hcv 저해제, 비뉴클레오시드 및 뉴클레오시드의 배합물 |
PE20140608A1 (es) | 2010-09-22 | 2014-06-12 | Alios Biopharma Inc | Analogos de nucleotidos sustituidos |
WO2012040124A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2013039920A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
EP2768838A1 (en) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE |
NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
EP2852605B1 (en) | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphate prodrugs for hcv infection |
AP3913A (en) | 2012-05-22 | 2016-11-26 | Idenix Pharamaceuticals Inc | D-amino acid compounds for liver disease |
UY34824A (es) | 2012-05-25 | 2013-11-29 | Janssen R & D Ireland | Nucleósidos de espirooxetano de uracilo |
EP2900682A1 (en) | 2012-09-27 | 2015-08-05 | IDENIX Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
PE20151318A1 (es) | 2012-10-08 | 2015-10-03 | Idenix Pharmaceuticals Inc | Analogos de 2'-cloro nucleosido para infeccion por vhc |
US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
KR102327888B1 (ko) * | 2012-12-21 | 2021-11-17 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체 |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
EP3004130B1 (en) | 2013-06-05 | 2019-08-07 | Idenix Pharmaceuticals LLC. | 1',4'-thio nucleosides for the treatment of hcv |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
UA117375C2 (uk) * | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
EP3131914B1 (en) | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6339752A (ja) | 1986-08-02 | 1988-02-20 | Kawada Tekko Kk | インデツクス装置 |
SE8701605D0 (sv) | 1987-04-16 | 1987-04-16 | Astra Ab | Novel medicinal compounds |
DE3715666A1 (de) | 1987-05-11 | 1988-11-24 | Kodak Ag | Kassettenentlade- und beladegeraet |
GB8712115D0 (en) | 1987-05-22 | 1987-06-24 | Hoffmann La Roche | Pyrimidine derivatives |
US5246924A (en) * | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
SE8802173D0 (sv) | 1988-06-10 | 1988-06-10 | Astra Ab | Pyrimidine derivatives |
SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
HUT51643A (en) * | 1988-11-21 | 1990-05-28 | Syntex Inc | Process for producing antiviral agents and pharmaceutical compositions comprising same as active ingredient |
US5034518A (en) * | 1989-05-23 | 1991-07-23 | Southern Research Institute | 2-fluoro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine nucleosides |
WO1991015470A1 (en) | 1990-03-30 | 1991-10-17 | Eastman Kodak Company | Alcohol-ester separation by reaction with acetate |
AU7623991A (en) * | 1990-05-17 | 1991-11-21 | Syntex (U.S.A.) Inc. | Antiviral agents |
IT1249732B (it) | 1991-11-26 | 1995-03-09 | Angeletti P Ist Richerche Bio | Oligonucleotidi antisenso. |
US5418151A (en) | 1992-08-07 | 1995-05-23 | Genencor International, Inc. | Regio-selective process for resolution of carbohydrate monoesters |
US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
BR9908270A (pt) * | 1998-02-25 | 2004-06-29 | Univ Emory | 2-fluoro-nucleosìdeos, composições farmacêuticas e seus usos |
AU756627B2 (en) | 1998-07-27 | 2003-01-16 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Diketoacid-derivatives as inhibitors of polymerases |
AU743411B2 (en) | 1998-08-21 | 2002-01-24 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
US6440985B1 (en) | 1998-09-04 | 2002-08-27 | Viropharma Incorporated | Methods for treating viral infections |
CN1324212A (zh) | 1998-09-25 | 2001-11-28 | 维洛药品公司 | 治疗或预防病毒感染及有关疾病的方法 |
DE60005502T2 (de) | 1999-05-12 | 2004-06-24 | Yamasa Corp., Choshi | 4'-c-ethynyl-purin-nukleoside |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
WO2001047833A1 (fr) | 1999-12-24 | 2001-07-05 | Asahi Glass Company, Limited | Filtre au nitrure de silicium et procede de fabrication correspondant |
WO2001077091A2 (en) | 2000-04-05 | 2001-10-18 | Tularik Inc. | Ns5b hcv polymerase inhibitors |
EP1292310A1 (en) | 2000-05-10 | 2003-03-19 | SmithKline Beecham Corporation | Novel anti-infectives |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
NZ547204A (en) | 2000-05-26 | 2008-01-31 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
WO2002005787A1 (fr) | 2000-07-17 | 2002-01-24 | Takeda Chemical Industries, Ltd. | Fabrication pour produits lyophilises |
GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
MXPA03006514A (es) | 2001-01-22 | 2004-12-02 | Merck & Co Inc | Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico. |
US6677120B2 (en) | 2001-03-30 | 2004-01-13 | Isis Pharmaceuticals, Inc. | Building blocks for the solution phase synthesis of oligonucleotides |
KR100798579B1 (ko) | 2001-03-31 | 2008-01-28 | 동화약품공업주식회사 | 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물 |
AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
ATE438637T1 (de) | 2001-06-11 | 2009-08-15 | Virochem Pharma Inc | Thiophenderivate als antivirale mittel gegen flavivirus-infektion |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
US6841566B2 (en) | 2001-07-20 | 2005-01-11 | Boehringer Ingelheim, Ltd. | Viral polymerase inhibitors |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
US6899700B2 (en) | 2001-08-29 | 2005-05-31 | Kimberly-Clark Worldwide, Inc. | Therapeutic agent delivery tampon |
WO2003026675A1 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
AU2002330154A1 (en) | 2001-09-28 | 2003-04-07 | Centre National De La Recherche Scientifique | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
WO2003037262A2 (en) | 2001-10-29 | 2003-05-08 | Smithkline Beecham Corporation | Novel anit-infectives |
AU2002365198A1 (en) | 2001-10-30 | 2003-07-30 | Smithkline Beecham Corporation | Novel anti-infectives |
AU2002351077A1 (en) | 2001-11-05 | 2003-05-19 | Exiqon A/S | Oligonucleotides modified with novel alpha-l-rna analogues |
WO2003052248A1 (es) | 2001-12-18 | 2003-06-26 | Fernandez Del Castillo Y Simon | Multipiston en columna |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
WO2003099801A1 (en) | 2002-05-24 | 2003-12-04 | Smithkline Beecham Corporation | Novel anti-infectives |
WO2004002999A2 (en) | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
AU2003248748A1 (en) * | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
PL374792A1 (en) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
EP2361913A1 (en) | 2002-11-01 | 2011-08-31 | Abbott Laboratories | Anti-infective agents |
NO319194B1 (no) | 2002-11-14 | 2005-06-27 | Pronova Biocare As | Lipase-katalysert forestringsfremgangsmate av marine oljer |
KR20050088079A (ko) | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이 |
TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
TWI294882B (en) * | 2002-12-09 | 2008-03-21 | Hoffmann La Roche | Anhydrous crystalline azido cytosine hemisulfate derivative |
WO2004052313A2 (en) | 2002-12-11 | 2004-06-24 | Smithkline Beecham Corporation | Anti-infectives |
WO2004052312A2 (en) | 2002-12-11 | 2004-06-24 | Smithkline Beecham Corporation | Anti-infectives |
AU2003297235A1 (en) | 2002-12-17 | 2004-07-22 | Smithkline Beecham Corporation | Anti-infectives |
US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
EP1644395B1 (en) | 2003-06-19 | 2006-11-22 | F. Hoffmann-La Roche Ag | Processes for preparing 4'azido nucleoside derivatives |
US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
WO2005019191A2 (en) | 2003-08-25 | 2005-03-03 | Abbott Laboratories | 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c |
US7642235B2 (en) | 2003-09-22 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
ATE461209T1 (de) | 2004-01-30 | 2010-04-15 | Medivir Ab | Hcv ns-3 serine protease inhibitoren |
WO2006021340A1 (en) | 2004-08-23 | 2006-03-02 | F.Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
CA2577526A1 (en) * | 2004-08-23 | 2006-03-02 | Joseph Armstrong Martin | Antiviral 4'-azido-nucleosides |
AP2009004812A0 (en) * | 2006-10-10 | 2009-04-30 | Medivir Ab | HCV nucleoside inhibitor |
-
2007
- 2007-10-04 AP AP2009004812A patent/AP2009004812A0/xx unknown
- 2007-10-04 AT AT07820934T patent/ATE493428T1/de active
- 2007-10-04 PL PL10196341T patent/PL2361922T3/pl unknown
- 2007-10-04 WO PCT/EP2007/060557 patent/WO2008043704A1/en active Application Filing
- 2007-10-04 JP JP2009531813A patent/JP2010505902A/ja not_active Ceased
- 2007-10-04 PT PT07820934T patent/PT2084175E/pt unknown
- 2007-10-04 AU AU2007306405A patent/AU2007306405A1/en not_active Abandoned
- 2007-10-04 DK DK07820934.3T patent/DK2084175T3/da active
- 2007-10-04 NZ NZ575889A patent/NZ575889A/en not_active IP Right Cessation
- 2007-10-04 RS RS20110127A patent/RS51643B/en unknown
- 2007-10-04 EA EA200970358A patent/EA018935B1/ru not_active IP Right Cessation
- 2007-10-04 BR BRPI0719258-4A2A patent/BRPI0719258A2/pt active Search and Examination
- 2007-10-04 DE DE602007011658T patent/DE602007011658D1/de active Active
- 2007-10-04 ES ES07820934T patent/ES2358853T3/es active Active
- 2007-10-04 EP EP10196341A patent/EP2361922B1/en active Active
- 2007-10-04 PL PL07820934T patent/PL2084175T3/pl unknown
- 2007-10-04 EP EP07820934A patent/EP2084175B1/en active Active
- 2007-10-04 MY MYPI20091428A patent/MY145314A/en unknown
- 2007-10-04 KR KR1020097009591A patent/KR20090078347A/ko not_active Application Discontinuation
- 2007-10-04 SI SI200730544T patent/SI2084175T1/sl unknown
- 2007-10-04 CN CN2007800379054A patent/CN101573370B/zh not_active Expired - Fee Related
- 2007-10-04 ES ES10196341T patent/ES2392948T3/es active Active
- 2007-10-04 MX MX2009003452A patent/MX2009003452A/es active IP Right Grant
- 2007-10-04 CN CN201010274006XA patent/CN101979397B/zh not_active Expired - Fee Related
- 2007-10-04 CA CA2665049A patent/CA2665049C/en not_active Expired - Fee Related
- 2007-10-10 US US11/973,681 patent/US7666856B2/en not_active Expired - Fee Related
-
2009
- 2009-03-31 GT GT200900069A patent/GT200900069A/es unknown
- 2009-03-31 CO CO09033094A patent/CO6180441A2/es not_active Application Discontinuation
- 2009-04-05 IL IL197907A patent/IL197907A0/en unknown
- 2009-04-09 ZA ZA200902496A patent/ZA200902496B/xx unknown
- 2009-04-13 HN HN2009000614A patent/HN2009000614A/es unknown
- 2009-05-11 NO NO20091834A patent/NO20091834L/no not_active Application Discontinuation
- 2009-05-11 CR CR10789A patent/CR10789A/es not_active Application Discontinuation
-
2010
- 2010-01-20 US US12/690,842 patent/US7825239B2/en not_active Expired - Fee Related
- 2010-01-29 HK HK10101044.2A patent/HK1137459A1/xx not_active IP Right Cessation
- 2010-09-24 US US12/890,538 patent/US7935681B2/en not_active Expired - Fee Related
-
2011
- 2011-03-16 HR HR20110193T patent/HRP20110193T1/hr unknown
- 2011-03-17 CY CY20111100298T patent/CY1111342T1/el unknown
- 2011-03-28 US US13/073,821 patent/US8158779B2/en not_active Expired - Fee Related
- 2011-07-29 JP JP2011167159A patent/JP2011246485A/ja not_active Ceased
- 2011-08-02 HK HK11108019.7A patent/HK1154247A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6180441A2 (es) | Inhibidores nucleosidos del hcv | |
GT200800170A (es) | Compuestos de n-formil-hidroxilamina | |
GT200800258A (es) | Compuestos de pirrolo-pirimidina y sus usos | |
AR062797A1 (es) | Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas. | |
UY30603A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica | |
AR056686A1 (es) | Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas | |
AR083058A1 (es) | Compuestos de estructura de imidazotriazinona | |
MX357131B (es) | Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso. | |
UA101328C2 (uk) | Похідні 6-триазолпіридинсульфанілбензотіазолу і -бензімідазолу, спосіб їх одержання (варіанти), застосування їх як лікарських засобів, фармацевтична композиціїя та застосування як інгібіторів met | |
UY30004A1 (es) | Metodos y kits para dosificar nucléosidos antivirales beta-d-2´, 3´-didehidro-2´, 3´- dideoxi-5-fluorocitidina | |
AR074504A1 (es) | Nucleotidos uracil ciclopropilicos | |
ECSP088965A (es) | Derivados de 2-tioxantina que actúan como inhibidores de la mpo | |
AR088625A1 (es) | Derivados de aril-quinolina | |
EA201600241A1 (ru) | Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты | |
AR064424A1 (es) | Derivados sustituidos de 1-oxo-ftalazinas y 1-oxo-pirido-piridazinas,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar enfermedades inflamatorias y alergicas del tracto respiratorio. | |
AR053345A1 (es) | Compuesto de 1,2,4 triazolo-5-ona como inhibidores de la transcriptasa inversa | |
AR054266A1 (es) | Indoles sustituidos con piperidina | |
DE602006000226D1 (de) | Verfahren zur Herstellung von Adapalene | |
ATE547100T1 (de) | Leberfibroseinhibitor | |
ATE514702T1 (de) | Verfahren zur herstellung von clopidogrel und dabei verwendete zwischenprodukte | |
HN2010001700A (es) | Procedimiento de preparacion de combretastatina | |
CO6270185A2 (es) | Derivados de isotiazol y pirazol como fungicidas | |
SG154418A1 (en) | Granular composition and production thereof | |
ES2546833T3 (es) | Derivados de pirrolidina como antagonistas de receptores de NK-3 | |
AR065724A1 (es) | Macrolidos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |